Theseus Pharmaceuticals THRX Stock
Theseus Pharmaceuticals Price Chart
Theseus Pharmaceuticals THRX Financial and Trading Overview
| Theseus Pharmaceuticals stock price | 4.06 USD |
| Previous Close | 8.94 USD |
| Open | 8.9 USD |
| Bid | 0 USD x 1100 |
| Ask | 0 USD x 1100 |
| Day's Range | 8.68 - 9.31 USD |
| 52 Week Range | 4.01 - 14.77 USD |
| Volume | 77.03K USD |
| Avg. Volume | 145.18K USD |
| Market Cap | 393.5M USD |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | 0 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 22.29 USD |
THRX Valuation Measures
| Enterprise Value | 154.81M USD |
| Trailing P/E | N/A |
| Forward P/E | -4.470297 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 1.5945611 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -2.559 |
Trading Information
Theseus Pharmaceuticals Stock Price History
| Beta (5Y Monthly) | N/A |
| 52-Week Change | 56.49% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 14.77 USD |
| 52 Week Low | 4.01 USD |
| 50-Day Moving Average | 9.93 USD |
| 200-Day Moving Average | 8.24 USD |
THRX Share Statistics
| Avg. Volume (3 month) | 145.18K USD |
| Avg. Daily Volume (10-Days) | 84.6K USD |
| Shares Outstanding | 43.58M |
| Float | 16.75M |
| Short Ratio | 5.18 |
| % Held by Insiders | 1.38% |
| % Held by Institutions | 78.73% |
| Shares Short | 1.12M |
| Short % of Float | 5.59% |
| Short % of Shares Outstanding | 2.57% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -15.045% |
| Return on Equity (ttm) | -22.63% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -60493000 USD |
| Net Income Avi to Common (ttm) | -54697000 USD |
| Diluted EPS (ttm) | -1.38 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 236.63M USD |
| Total Cash Per Share (mrq) | 5.46 USD |
| Total Debt (mrq) | 3.88M USD |
| Total Debt/Equity (mrq) | 1.58 USD |
| Current Ratio (mrq) | 36.594 |
| Book Value Per Share (mrq) | 5.663 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -43891000 USD |
| Levered Free Cash Flow (ttm) | -27026250 USD |
Profile of Theseus Pharmaceuticals
| Country | United States |
| State | MA |
| City | Cambridge |
| Address | 314 Main Street |
| ZIP | 02142 |
| Phone | 857 400 9491 |
| Website | https://theseusrx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 38 |
Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors. The company also develops THE-349, a fourth-generation selective epidermal growth factor receptor inhibitor to address C797X-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer. Its development programs address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
Q&A For Theseus Pharmaceuticals Stock
What is a current THRX stock price?
Theseus Pharmaceuticals THRX stock price today per share is 4.06 USD.
How to purchase Theseus Pharmaceuticals stock?
You can buy THRX shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Theseus Pharmaceuticals?
The stock symbol or ticker of Theseus Pharmaceuticals is THRX.
Which industry does the Theseus Pharmaceuticals company belong to?
The Theseus Pharmaceuticals industry is Biotechnology.
How many shares does Theseus Pharmaceuticals have in circulation?
The max supply of Theseus Pharmaceuticals shares is 44.65M.
What is Theseus Pharmaceuticals Price to Earnings Ratio (PE Ratio)?
Theseus Pharmaceuticals PE Ratio is 0.00000000 now.
What was Theseus Pharmaceuticals earnings per share over the trailing 12 months (TTM)?
Theseus Pharmaceuticals EPS is 0 USD over the trailing 12 months.
Which sector does the Theseus Pharmaceuticals company belong to?
The Theseus Pharmaceuticals sector is Healthcare.
Theseus Pharmaceuticals THRX included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| NASDAQ Global Select Market Com NQGS | 7876.03 USD — |
-1.61
|
— — | 7852.08 USD — | 7955.84 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
| NASDAQ Composite Total Return I XCMP | 19659.36 USD — |
-1.62
|
— — | 19598.88 USD — | 19861.56 USD — | — - | — — |
- {{ link.label }} {{link}}